Therapeutic strategies using cytokines have not been extensively tested in patients with advanced non-small-cell lung cancer (NSCLC). We developed a basic laboratory and clinical research program to investigate the effective immunotherapeutic manipulations for activating the endogenous immune system with biological agents. Our efforts using low-dose interleukin 2 in conjunction with other biologic response modifiers for the treatment of NSCLC are summarized here.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of the National Cancer Institute. Monographs|
|State||Published - 1992|
ASJC Scopus subject areas
- Cancer Research